Get the Stockscreener App
18.06
4.80%
-0.91
After Hours:
18.06
Nurix Therapeutics Inc stock is traded at $18.06, with a volume of 1.47M.
It is down -4.80% in the last 24 hours and up +10.46% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$18.97
Open:
$19
24h Volume:
1.47M
Relative Volume:
0.86
Market Cap:
$1.83B
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-6.2491
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-6.42%
1M Performance:
+10.46%
6M Performance:
+45.18%
1Y Performance:
-7.43%
1-Day Range:
$17.86
$19.03
1-Week Range:
$17.86
$19.54
52-Week Range:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
18.06 | 1.92B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics Inc Stock Analysis and ForecastMarket Sentiment Extremes & High-Risk, High-Reward? We Find the Winners - earlytimes.in
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)? - Yahoo Finance
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Insider Monkey
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance
Should I hold or sell Nurix Therapeutics Inc. stock in 20252025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
Stock Analysis: Is Nurix Therapeutics Inc. stock a defensive play in 2025Quarterly Performance Summary & AI Forecasted Entry and Exit Points - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Does New NX-5948 Phase 2 Dose Selection Change The Bull Case For Nurix Therapeutics (NRIX)? - simplywall.st
Is Nurix Therapeutics Inc. stock a defensive play in 2025Index Update & Stepwise Entry/Exit Trade Alerts - Улправда
Will Nurix Therapeutics Inc. stock gain from lower inflationEarnings Trend Report & Reliable Price Breakout Alerts - Улправда
Sell Signal: Is Nurix Therapeutics Inc. stock a defensive play in 2025 - Улправда
Why Nurix Therapeutics Inc. stock appeals to analysts2025 Market Overview & Pattern Based Trade Signal System - ulpravda.ru
Nurix Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
Officer Ring Sells 3,760 ($67.3K) Of Nurix Therapeutics Inc [NRIX] - TradingView — Track All Markets
Nurix Therapeutics (NRIX) Chief Legal Officer reports option exercise and stock sales - Stock Titan
Why Nurix Therapeutics Inc. stock could outperform in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Institution Moves: Why Nurix Therapeutics Inc. stock appeals to analystsMarket Sentiment Summary & Fast Entry Momentum Trade Alerts - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 4%Here's What Happened - MarketBeat
Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients - TipRanks
Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Given New $30.00 Price Target at Wells Fargo & Company - MarketBeat
Cathie Wood Sells $40M in Tesla, Keeps Cutting Iridium, and Adds Nurix: What ARK Invest’s Latest Trades Signal on Dec. 15, 2025 - ts2.tech
Nurix Therapeutics, Inc. $NRIX Shares Purchased by Nikko Asset Management Americas Inc. - MarketBeat
Redmile Group LLC Lowers Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Optimistic Investors Push Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Up 48% But Growth Is Lacking - 富途牛牛
Nurix prices 24.5M shares at $10.21 in underwritten registered offering - MSN
Nurix Therapeutics price target raised to $31 from $28 at HC Wainwright - MSN
Cathie Wood Reduces Iridium Holdings While Adding Biotech Stock Nurix Therapeutics - parameter.io
Why Cathie Wood Just Sold Millions in Iridium and Bought This Biotech Stock - CoinCentral
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday - Investing.com
What insider trading reveals about Nurix Therapeutics Inc stockMarket Activity Report & Risk Controlled Daily Plans - moha.gov.vn
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 at Mizuho - MarketBeat
Nurix stock price target raised to $31 from $28 at H.C. Wainwright - Investing.com UK
NRIX: HC Wainwright & Co. Raises Price Target for Nurix Therapeu - GuruFocus
Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating - marketscreener.com
Analysts’ Top Healthcare Picks: Mirum Pharmaceuticals (MIRM), Eli Lilly & Co (LLY) - The Globe and Mail
BTIG Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 5.4%Here's Why - MarketBeat
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):